|
August 31, 2021
|
Histogen to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
|
|
|
August 16, 2021
|
Histogen and Amerimmune Announce Additional Findings from its Phase 1 Study of Emricasan in Mild Symptomatic COVID-19 Patients
|
|
|
August 11, 2021
|
Histogen Reports Second Quarter 2021 Earnings and Provides Business Update
|
|
|
July 29, 2021
|
Histogen to Present at the Canaccord Genuity 41st Annual Growth Conference
|
|
|
July 28, 2021
|
Histogen to Report Second Quarter 2021 Financial Results on August 11, 2021
|
|
|
June 30, 2021
|
Histogen Announces Initiation of HST 003 Phase 1/2 Trial for Knee Cartilage Regeneration
|
|
|
June 22, 2021
|
Histogen and Amerimmune Announce Positive Top-Line Study Results from its Phase 1 Study of Emricasan in Mild Symptomatic COVID-19 Patients
|
|
|
June 9, 2021
|
Histogen Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
|
|
|
June 7, 2021
|
Histogen Announces $6.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
|
|
|
June 3, 2021
|
Histogen Provides Update on its Development Programs and Pipeline Focus
|
|
